tiprankstipranks
Trending News
More News >
Moderna (MRNA)
:MRNA
US Market
Advertisement

Moderna (MRNA) Stock Forecast & Price Target

Compare
17,402 Followers
See the Price Targets and Ratings of:

MRNA Analyst Ratings

Hold
20Ratings
Hold
3 Buy
14 Hold
3 Sell
Based on 20 analysts giving stock ratings to
Moderna
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRNA Stock 12 Month Forecast

Average Price Target

$43.75
▲(59.26% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $43.75 with a high forecast of $198.00 and a low forecast of $18.00. The average price target represents a 59.26% change from the last price of $27.47.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","108":"$108","199":"$199","62.5":"$62.5","153.5":"$153.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$198.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,62.5,108,153.5,199],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,40.70769230769231,53.815384615384616,66.92307692307693,80.03076923076924,93.13846153846154,106.24615384615385,119.35384615384615,132.46153846153845,145.56923076923076,158.67692307692306,171.78461538461536,184.8923076923077,{"y":198,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,28.842307692307692,30.084615384615386,31.326923076923077,32.56923076923077,33.81153846153846,35.05384615384615,36.29615384615384,37.53846153846154,38.78076923076923,40.02307692307692,41.26538461538462,42.50769230769231,{"y":43.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.6,26.861538461538462,26.123076923076923,25.384615384615387,24.646153846153847,23.907692307692308,23.16923076923077,22.43076923076923,21.692307692307693,20.953846153846154,20.215384615384615,19.47692307692308,18.738461538461536,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":94.17,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.58,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.42,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":30.96,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.69,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$198.00Average Price Target$43.75Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MRNA
TipRanks AITipRanks
Not Ranked
TipRanks
$27
Hold
-1.71%
Downside
Reiterated
08/03/25
Moderna's overall stock score is impacted primarily by its financial challenges and bearish technical indicators. While there are positive strategic shifts and cost management efforts, revenue declines and profitability issues are significant concerns. The earnings call provided some positive outlooks, but the valuation remains unattractive due to ongoing losses.
Evercore ISI Analyst forecast on MRNA
Cory KasimovEvercore ISI
Evercore ISI
$32
Hold
16.49%
Upside
Reiterated
08/04/25
Moderna (MRNA) Gets a Hold from Evercore ISI
Bank of America Securities Analyst forecast on MRNA
Tim AndersonBank of America Securities
Bank of America Securities
$25$24
Sell
-12.63%
Downside
Reiterated
08/04/25
Moderna's Financial Outlook: Sell Rating Amid Revenue Challenges and Reliance on COVID-19
Barclays Analyst forecast on MRNA
Gena WangBarclays
Barclays
$40$31
Hold
12.85%
Upside
Reiterated
08/04/25
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and MiMedx Group (NASDAQ: MDXG)
Citi
$35$30
Hold
9.21%
Upside
Reiterated
08/04/25
Analysts' Top Healthcare Picks: Moderna (MRNA), Centene (CNC)
Morgan Stanley Analyst forecast on MRNA
Terence FlynnMorgan Stanley
Morgan Stanley
$31
Hold
12.85%
Upside
Reiterated
08/04/25
Moderna's Hold Rating: Navigating Revenue Adjustments and Product Development Uncertainties
Berenberg Bank Analyst forecast on MRNA
Harry GillisBerenberg Bank
Berenberg Bank
$30
Hold
9.21%
Upside
Reiterated
08/04/25
Berenberg Bank Sticks to Their Hold Rating for Moderna (MRNA)
UBS
$70
Buy
154.82%
Upside
Reiterated
08/04/25
UBS Remains a Buy on Moderna (MRNA)
Leerink Partners Analyst forecast on MRNA
Mani ForooharLeerink Partners
Leerink Partners
$20$18
Sell
-34.47%
Downside
Reiterated
08/04/25
Moderna (MRNA) Receives a Sell from Leerink Partners
Oppenheimer Analyst forecast on MRNA
Unknown AnalystOppenheimer
Not Ranked
Oppenheimer
Hold
Reiterated
08/04/25
Oppenheimer Remains a Hold on Moderna (MRNA)
William Blair Analyst forecast on MRNA
Myles MinterWilliam Blair
William Blair
Hold
Reiterated
08/01/25
Moderna's Financial Outlook: Hold Rating Amid Revenue Challenges and Cost-Cutting MeasuresWe attribute lack of mRESVIA revenue to seasonal trends in vaccine uptake as well as restrictive recommendations from the Advisory Council on Immunization Practice’s (ACIP) regarding re- dosing.
Needham
Hold
Reiterated
08/01/25
Moderna's Hold Rating: Navigating Revenue Volatility and Strategic Shifts Amidst Pipeline PotentialWe believe MRNA's vaccine franchise (COVID, RSV , Flu, etc.) will continue to face headwinds in the near term. The rare disease pipeline is intriguing but not yet a major value driver. We believe the oncology pipeline has the most upside potential, but we don't expect major data catalysts from this program until 2026+. Maintain Hold. Disclaimers JOSEPH STRINGER, PH.D.
Bernstein
$28
Hold
1.93%
Upside
Assigned
08/01/25
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Regeneron (NASDAQ: REGN)
TD Cowen
$30$25
Hold
-8.99%
Downside
Reiterated
08/01/25
Cautious Outlook for Moderna Amid Revenue Uncertainties Warrants Hold Rating
RBC Capital Analyst forecast on MRNA
Luca IssiRBC Capital
RBC Capital
$28
Hold
1.93%
Upside
Reiterated
08/01/25
RBC Capital Keeps Their Hold Rating on Moderna (MRNA)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MRNA
TipRanks AITipRanks
Not Ranked
TipRanks
$27
Hold
-1.71%
Downside
Reiterated
08/03/25
Moderna's overall stock score is impacted primarily by its financial challenges and bearish technical indicators. While there are positive strategic shifts and cost management efforts, revenue declines and profitability issues are significant concerns. The earnings call provided some positive outlooks, but the valuation remains unattractive due to ongoing losses.
Evercore ISI Analyst forecast on MRNA
Cory KasimovEvercore ISI
Evercore ISI
$32
Hold
16.49%
Upside
Reiterated
08/04/25
Moderna (MRNA) Gets a Hold from Evercore ISI
Bank of America Securities Analyst forecast on MRNA
Tim AndersonBank of America Securities
Bank of America Securities
$25$24
Sell
-12.63%
Downside
Reiterated
08/04/25
Moderna's Financial Outlook: Sell Rating Amid Revenue Challenges and Reliance on COVID-19
Barclays Analyst forecast on MRNA
Gena WangBarclays
Barclays
$40$31
Hold
12.85%
Upside
Reiterated
08/04/25
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and MiMedx Group (NASDAQ: MDXG)
Citi
$35$30
Hold
9.21%
Upside
Reiterated
08/04/25
Analysts' Top Healthcare Picks: Moderna (MRNA), Centene (CNC)
Morgan Stanley Analyst forecast on MRNA
Terence FlynnMorgan Stanley
Morgan Stanley
$31
Hold
12.85%
Upside
Reiterated
08/04/25
Moderna's Hold Rating: Navigating Revenue Adjustments and Product Development Uncertainties
Berenberg Bank Analyst forecast on MRNA
Harry GillisBerenberg Bank
Berenberg Bank
$30
Hold
9.21%
Upside
Reiterated
08/04/25
Berenberg Bank Sticks to Their Hold Rating for Moderna (MRNA)
UBS
$70
Buy
154.82%
Upside
Reiterated
08/04/25
UBS Remains a Buy on Moderna (MRNA)
Leerink Partners Analyst forecast on MRNA
Mani ForooharLeerink Partners
Leerink Partners
$20$18
Sell
-34.47%
Downside
Reiterated
08/04/25
Moderna (MRNA) Receives a Sell from Leerink Partners
Oppenheimer Analyst forecast on MRNA
Unknown AnalystOppenheimer
Not Ranked
Oppenheimer
Hold
Reiterated
08/04/25
Oppenheimer Remains a Hold on Moderna (MRNA)
William Blair Analyst forecast on MRNA
Myles MinterWilliam Blair
William Blair
Hold
Reiterated
08/01/25
Moderna's Financial Outlook: Hold Rating Amid Revenue Challenges and Cost-Cutting MeasuresWe attribute lack of mRESVIA revenue to seasonal trends in vaccine uptake as well as restrictive recommendations from the Advisory Council on Immunization Practice’s (ACIP) regarding re- dosing.
Needham
Hold
Reiterated
08/01/25
Moderna's Hold Rating: Navigating Revenue Volatility and Strategic Shifts Amidst Pipeline PotentialWe believe MRNA's vaccine franchise (COVID, RSV , Flu, etc.) will continue to face headwinds in the near term. The rare disease pipeline is intriguing but not yet a major value driver. We believe the oncology pipeline has the most upside potential, but we don't expect major data catalysts from this program until 2026+. Maintain Hold. Disclaimers JOSEPH STRINGER, PH.D.
Bernstein
$28
Hold
1.93%
Upside
Assigned
08/01/25
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA) and Regeneron (NASDAQ: REGN)
TD Cowen
$30$25
Hold
-8.99%
Downside
Reiterated
08/01/25
Cautious Outlook for Moderna Amid Revenue Uncertainties Warrants Hold Rating
RBC Capital Analyst forecast on MRNA
Luca IssiRBC Capital
RBC Capital
$28
Hold
1.93%
Upside
Reiterated
08/01/25
RBC Capital Keeps Their Hold Rating on Moderna (MRNA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

1 Month
xxx
Success Rate
27/45 ratings generated profit
60%
Average Return
+0.28%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.28% per trade.
3 Months
xxx
Success Rate
27/45 ratings generated profit
60%
Average Return
-5.96%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of -5.96% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
37/45 ratings generated profit
78%
Average Return
-1.45%
reiterated a sell rating 5 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of -1.45% per trade.
2 Years
xxx
Success Rate
39/45 ratings generated profit
87%
Average Return
+32.02%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +32.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRNA Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
3
5
6
6
4
Buy
0
0
0
0
0
Hold
22
30
42
44
38
Sell
10
7
8
9
8
Strong Sell
0
0
0
0
0
total
35
42
56
59
50
In the current month, MRNA has received 4 Buy Ratings, 38 Hold Ratings, and 8 Sell Ratings. MRNA average Analyst price target in the past 3 months is 43.75.
Each month's total comprises the sum of three months' worth of ratings.

MRNA Financial Forecast

MRNA Earnings Forecast

Next quarter’s earnings estimate for MRNA is -$2.07 with a range of -$3.19 to -$0.75. The previous quarter’s EPS was -$2.13. MRNA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 46.24% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.
Next quarter’s earnings estimate for MRNA is -$2.07 with a range of -$3.19 to -$0.75. The previous quarter’s EPS was -$2.13. MRNA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 46.24% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.

MRNA Sales Forecast

Next quarter’s sales forecast for MRNA is $933.78M with a range of $610.94M to $1.43B. The previous quarter’s sales results were $142.00M. MRNA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 51.72% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.
Next quarter’s sales forecast for MRNA is $933.78M with a range of $610.94M to $1.43B. The previous quarter’s sales results were $142.00M. MRNA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 51.72% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.

MRNA Stock Forecast FAQ

What is MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is 43.75.
    What is MRNA’s upside potential, based on the analysts’ average price target?
    Moderna has 59.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRNA a Buy, Sell or Hold?
          Moderna has a consensus rating of Hold which is based on 3 buy ratings, 14 hold ratings and 3 sell ratings.
            What is Moderna’s price target?
            The average price target for Moderna is 43.75. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $198.00 ,the lowest forecast is $18.00. The average price target represents 59.26% Increase from the current price of $27.47.
              What do analysts say about Moderna?
              Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of MRNA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis